DBV Technologies shares drop 12.5% in one week, among the weakest in the SBF 120
The Châtillon-based biotech closes the session near the bottom of the Paris index, in a European market trending lower. The stock extends a decline that has been ongoing for several days, despite a rebound over one month.
A weekly decline that pushes the stock below its moving averages
The share price of DBV Technologies falls 2.94% to €1.75 and is among the largest decliners in the SBF 120, which drops 0.82%. Over seven days, the loss reaches 12.76%, while the stock remains up 11.61% over one month.
The price is now below its 20-day moving average (MM20) at €1.84 (a gap of 4.89%) and its 50-day moving average (MM50) at €1.89, erasing the rebound seen in early November.
The RSI at 44 remains neutral: the move reflects profit-taking after the monthly rise, not an oversold situation. The €1.57 support, approached at the end of October, remains the nearest level on the downside.
An ongoing FDA review and net short positions at 3.49% of share capital
Declared net short positions reach 3.49% of share capital, spread across five funds, up 0.60 point over thirty days. At this level, a notable portion of the capital remains positioned for a decline, with pressure that has intensified over the past month. This figure reflects a bearish bet, without giving the reasons behind it.
On the fundamentals, when publishing its accounts on October 28, 2026, the company reported a doubt about its going concern, and its short-term financing requirement extends beyond the third quarter of 2027.
Meanwhile, the FDA decision on the Viaskin Peanut patch in children aged 4 to 7 is expected in the fourth quarter of 2026: it is the nearest regulatory milestone for the stock.